- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Three-Year Imatinib Regimen Delivers Optimal GIST Treatment
June 6th 2011, 6:47am
3 years of treatment with imatinib (Gleevec) after surgery in patients with high-risk GIST improved overall and recurrence-free survival
Pemetrexed Maintenance Improves Progression-Free Survival in Patients With NSCLC
June 6th 2011, 6:37am
Continuation maintenance with pemetrexed (Alimta) improves progression-free survival in patients with advanced nonsquamous non–small cell lung cancer
Dr. Wolchok Describes the Immunotherapy Ipilimumab
June 6th 2011, 6:26am
Dr. Wolchok from Memorial Sloan-Kettering Cancer Center Describes the Immunotherapy Ipilimumab
Dr. Kris on the Use of Genetic Testing in Lung Cancer
June 6th 2011, 5:38am
Dr. Kris From Memorial Sloan-Kettering Cancer Center on the Use of Genetic Testing in Lung Cancer
MEK and BRAF Therapy Combo Promising for Advanced Melanoma
June 5th 2011, 2:10pm
The combination of the MEK inhibitor GSK212 and the oral BRAF inhibitor GSK436 resulted in anti-tumor activity in patients with advanced melanoma
Dr. Virgo on Survivorship Care Training & Policies
June 5th 2011, 12:15pm
Dr. Katherine Virgo from the American Cancer Society Discusses Survivorship Care Training & Policies
Dr. Hoos on the Patients That Respond to Ipilimumab
June 5th 2011, 11:48am
Dr. Axel Hoos from Bristol Myers-Squib on the Patients That Respond to Ipilimumab
Dr. Chapman Describes the Side Effects of Vemurafenib
June 5th 2011, 11:43am
Dr. Paul Chapman from Memorial Sloan-Kettering Cancer Center Describes the Side Effects of Vemurafenib
Dr. Tsimberidou Discusses Improving Care
June 5th 2011, 11:23am
Apostolia M. Tsimberidou, MD, PhD, from MD Anderson Cancer Center discusses improving cancer care.
Dr. Cella on Patient Assessment Reference Scores
June 5th 2011, 11:07am
Dr. Cella from Northwestern University Feinberg School of Medicine on Patient Assessment Reference Scores
Genetic Testing Delivers Personalized Lung Cancer Therapy
June 5th 2011, 10:24am
Taking a page from breast cancer treatment, clinicians managing lung cancer patients can now detect mutations that drive the development of lung cancer
NKTR-102 Shows Promise in Phase II Trial
June 5th 2011, 9:58am
Metastatic breast cancer patients with demonstrated disease progression after taxane therapy face an uphill battle in fighting their disease.
Circulating Tumor Cells Show Promise as Surrogate for Survival in Prostate Cancer Trials
June 5th 2011, 6:31am
Prostate cancer research lacks surrogate biomarkers for survival that could hasten the study and approval of new medications.
Regional Radiation Therapy Improves Outcomes in Early Breast Cancer
June 5th 2011, 6:00am
Radiation therapy directed to the regional lymph nodes of women with early-stage breast cancer reduced distant disease recurrence
Amonafide Plus Cytarabine Fails To Meet Primary Endpoint
June 4th 2011, 10:08am
Amonafide+Cytarabine may not be effective for secondary acute myeloid leukemia, according to ACCEDE trial data
High-Dose Methotrexate Better for ALL
June 4th 2011, 9:54am
High doses of methotrexate increases EFS for children and young adults
Molecular Profiling Boosts Targeted Therapies in Phase I Trial
June 4th 2011, 9:14am
Matching patients with targeted therapies based on molecular profile results in superior clinical outcomes
Dr. Joensuu on the Imatinib for High-Risk GIST Trial
June 4th 2011, 7:51am
Dr. Heikki Joensuu from the Helsinki University Central Hospital Summarizes the Imatinib for High-Risk high-risk gastrointestinal stromal tumors (GIST) Trial
Tim Turnham Discusses Melanoma Treatment Advances
June 4th 2011, 6:13am
Tim Turnham the Executive Director of the Melanoma Research Foundation Discusses Melanoma Treatment Advances
Investors Taking Stock of Key ASCO Abstracts
May 19th 2011, 4:01pm
Oncology specialists, biopharmaceutical analysts and investors all await the latest research news from the upcoming ASCO annual meeting